200
Participants
Start Date
August 11, 2021
Primary Completion Date
June 30, 2026
Study Completion Date
December 31, 2026
177Lu-PSMA-617
IA of 7.4GBq (± 10%) IV every 6 weeks; maximum 6 cycles
Docetaxel
75mg/m2 IV every 3 weeks maximum 12 cycles
Tom Baker Cancer Centre, Calgary
Cross Cancer Institute, Edmonton
BCCA - Vancouver Cancer Centre, Vancouver
London Regional Cancer Program, London
Odette Cancer Centre, Toronto
University Health Network, Toronto
CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal
The Jewish General Hospital, Montreal
Hotel-Dieu de Quebec, Québec
CIUSSS de l'Estrie - Centre hospitalier, Sherbrooke
Collaborators (1)
Prostate Cancer Canada
OTHER
Novartis Pharmaceuticals
INDUSTRY
Canadian Cancer Trials Group
NETWORK